ERBB2 and colorectal carcinoma: Based on these aspects, the CRC growth in vitro and in preclinical models is significantly reduced by the combination of the following drugs, such as p38α inhibitors (SB202190, SB203580, and BIRB796), autophagy inhibitors (3MA and bafilomycin), MEK inhibitors (PD98059, UO126, and CI-1040), HER2 inhibitors (lapatinib), multi-kinase inhibitors (sorafenib), or chemotherapeutic agents (5-FU, irinotecan, and cisplatin), which promote a higher rate of apoptosis versus the single treatment [174].